ArticleJournal of cachexia, sarcopenia and muscle2019
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Article in Journal of cachexia, sarcopenia and muscle, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.European radiology · 2021Trial
- Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial.JMIR mHealth and uHealth · 2021Trial
- Systemic Inflammatory Biomarkers and Cancer-Associated Cachexia: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy.Journal of clinical medicine · 2026Article
- Determinants of skeletal muscle loss during initial treatment in patients with ovarian cancer: a brief report.Frontiers in oncology · 2026Article
- Prognostic implications of body composition changes in patients with non-metastatic pancreatic adenocarcinoma treated with mFOLFIRINOX.Frontiers in oncology · 2026Article
- Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.Cancer discovery · 2025Review
- Global trends in sarcopenia and cancer over the past 10 years: a bibliometric analysis.Discover oncology · 2025Article
- Primary tumor location is a risk factor for postoperative development of sarcopenia as a predictive marker for unfavorable outcomes in patients with colorectal cancer.International journal of clinical oncology · 2025Article
- Clinical significance of cachexia index determined by bioelectrical impedance analysis in patients with gastrointestinal cancer.Oncology letters · 2025Article
- An exploratory study of serum creatine kinase as a prognostic marker for patients with resectable pancreatic cancer: looking into the relationship with body composition.Nutrition journal · 2025Article
- CT-based skeletal muscle loss predicts long term prognosis in patients with distal cholangiocarcinoma undergone pancreaticoduodenectomy.Scientific reports · 2025Article
- Skeletal muscle index combined with IgM predicts prognosis in gastric cancer patients who underwent surgery.Frontiers in immunology · 2025Article
- Effects of parenteral nutrition + best supportive nutritional care vs. best supportive nutritional care alone on quality of life in patients with pancreatic cancer-a secondary analysis of PANUSCO.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.European radiology · 2024Article
- Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.ESMO open · 2024Article
- Call for standardization in assessment and reporting of muscle and adipose change using computed tomography analysis in oncology: A scoping review.Journal of cachexia, sarcopenia and muscle · 2023Article
- Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and worse prognosis.
methodsThis is a retrospective study on advanced PC patients treated at the Department of Oncology of Udine, Italy, from January 2012 to November 2017. Among 162 patients who received chemotherapy, 94 consecutive patients with an available computed tomography (CT) scan were retrospectively analyzed. The primary objective of our study was to explore if an early LSMM ≥ 10% (measured at first radiological evaluation and compared with baseline) and/or baseline sarcopenia may impact prognosis. Baseline sarcopenia was defined according to Prado's criteria. Skeletal muscle area was measured as cross-sectional areas (cm
resultsIn the whole cohort, 48% of patients were ≤70 years old, and 50% had metastatic disease. At baseline, 73% of patients had sarcopenia, and 16% presented a visceral fat area ≥ 44 cm
conclusionsEarly LSMM ≥ 10% has a negative prognostic role in advanced PC patients. Further prospective investigations are needed to confirm these preliminary data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.